Therachon
Webb29 aug. 2024 · About Therachon. Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Webb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare …
Therachon
Did you know?
http://theracion.com/ WebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions …
Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024 Webb8 maj 2024 · May 8, 2024. Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a pipeline to ...
WebbTherachon Holding AG The Company, through its subsidiaries, provides therapeutic treatments for devastating rare conditions. Therachon Holding serves patients in … WebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and …
Webb13 mars 2024 · Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2024 for $810 million. …
Webb8 maj 2024 · Under the terms of the agreement, Pfizer will acquire Therachon for $340 million upfront with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46 for the treatment of achondroplasia, a genetic condition and the most common form of short … photo printing on ceramic platesWebb26 mars 2024 · We gave two presentations on investigational apraglutide for the treatment of #ShortBowelSyndrome at #ASPEN19!1. Complete Ph 1 trial results 2. Data from head-to-head rat studies comparing apraglutide to other GLP-2 analogs. photo printing on acrylicWebb17 aug. 2024 · Therachon, a Swiss biotech company, has closed a $60 million round to fund its new developments in rare genetic disease treatments. how does rockauto warranty workWebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome … how does rock turn into soilhttp://therachon.com/research/ photo printing neathWebb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … how does rocket mortgage make moneyWebb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … how does rock tape work